A worldwide group of scientists from MacCallum Disease Center in Melbourne, Australia, inspected 391 growth tissues from around 270 multisite dissection tests gathered from 15 people with end-stage high-grade serous ovarian disease (HGSD). All of the post-mortem examination tests came from patients who had at first responded to their disease treatment treatments but had become impervious to them in a backslide. The examination utilized entire genome sequencing, designated quality sequencing, RNA-seq, proteomics, methylation, and multicolor immunofluorescence to varying degrees across the gathered examples. Analysts searched for variety inside and between metastatic locales, zeroing in on the quantity of obstruction systems